
|Videos|February 20, 2014
Sequencing Abiraterone and Enzalutamide in mCRPC
Author(s)Sumanta Kumar Pal, MD
Sumanta Kumar Pal, MD, assistant professor, genitourinary cancers, City of Hope, discusses sequencing abiraterone and enzalutamide for the treatment of metastatic castration-resistant prostate cancer (mCRPC).
Advertisement
Clinical Pearls
Sumanta Kumar Pal, MD, assistant professor, genitourinary cancers, City of Hope, discusses sequencing abiraterone and enzalutamide for the treatment of metastatic castration-resistant prostate cancer (mCRPC).
- This study is a retrospective analysis aiming to characterize the activity of abiraterone following enzalutamide and vice versa
- Data sets like these are becoming increasingly important and speak to potential resistance that evolves when a patient receives one drug or the other for mCRPC
- This study, as well as others, have shown that receiving one drug may compromise the efficacy of the second
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Gedatolisib Improves PFS in HR+/HER2-/PIK3CA-WT Advanced Breast Cancer
2
Alpelisib/Fulvestrant Improves PFS in Post-CDK4/6 HR+/HER2- Breast Cancer
3
FDA Approves Niraparib/Abiraterone Combo for BRCA2-Mutated mCSPC
4
Nadunolimab Misses Efficacy Mark in TNBC, Despite Strong OS
5









































